Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on June 20, 2003. The report discloses corporate governance actions taken by the Board of Directors during a regularly scheduled meeting on that date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate by-law amendments and does not contain financial performance data.
Material Changes
The primary material change reported is the amendment and restatement of the Company's by-laws. Specifically, the Board modified the timeframe for shareholders to nominate directors or bring business before an annual meeting:
- Standard Window: Shareholders must submit notices between 90 and 120 days prior to the anniversary of the preceding annual meeting.
- Exception for Date Changes: If the annual meeting date is not within 25 days of the anniversary, notice must be received by the 10th day following the public announcement of the meeting date.
- 2004 Meeting Specifics: For the 2004 annual meeting (assuming the date remains near April 25, 2004), nominations must be submitted between December 27, 2003 and January 26, 2004.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a disclosure of the by-law amendment under Item 5 (Other Events) and Item 7 (Exhibits).
Key Facts for Investor Verification
- Verify the specific dates for the 2004 annual shareholders meeting to confirm the applicable nomination window.
- Review the full text of the Amended By-Laws (Exhibit 3.1) for additional procedural requirements for shareholder proposals.
- Confirm that no other financial or operational events were reported in this specific filing.